- Home
- MYPS vs PLX Comparison
MYPS vs PLX Comparison
Compare MYPS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYPS
- PLX
- Stock Information
- Founded
- MYPS 2011
- PLX 1993
- Country
- MYPS United States
- PLX United States
- Employees
- MYPS N/A
- PLX N/A
- Industry
- MYPS EDP Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MYPS Technology
- PLX Health Care
- Exchange
- MYPS Nasdaq
- PLX Nasdaq
- Market Cap
- MYPS 131.5M
- PLX 127.4M
- IPO Year
- MYPS N/A
- PLX 1998
- Fundamental
- Price
- MYPS $1.02
- PLX $1.48
- Analyst Decision
- MYPS Buy
- PLX Strong Buy
- Analyst Count
- MYPS 6
- PLX 1
- Target Price
- MYPS $2.80
- PLX $15.00
- AVG Volume (30 Days)
- MYPS 256.4K
- PLX 548.7K
- Earning Date
- MYPS 08-04-2025
- PLX 08-14-2025
- Dividend Yield
- MYPS N/A
- PLX N/A
- EPS Growth
- MYPS N/A
- PLX N/A
- EPS
- MYPS N/A
- PLX 0.08
- Revenue
- MYPS $261,058,000.00
- PLX $61,948,000.00
- Revenue This Year
- MYPS N/A
- PLX $10.00
- Revenue Next Year
- MYPS $0.89
- PLX $83.13
- P/E Ratio
- MYPS N/A
- PLX $19.11
- Revenue Growth
- MYPS N/A
- PLX 62.79
- 52 Week Low
- MYPS $1.00
- PLX $0.89
- 52 Week High
- MYPS $2.29
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- MYPS 28.78
- PLX 46.48
- Support Level
- MYPS $1.00
- PLX $1.41
- Resistance Level
- MYPS $1.07
- PLX $1.68
- Average True Range (ATR)
- MYPS 0.06
- PLX 0.08
- MACD
- MYPS -0.00
- PLX 0.01
- Stochastic Oscillator
- MYPS 8.00
- PLX 25.93
About MYPS PLAYSTUDIOS Inc.
PLAYSTUDIOS Inc is engaged in gaming and related business. The Company develops and operates online and mobile social gaming applications (games or game), many of which incorporate a loyalty program offering real world rewards provided by a collection of awards partners. The Company's games are free-to-play and available via the Apple App Store, Google Play Store, Amazon Appstore and Facebook (collectively, platforms or platform operators). The Company creates games based on its own original content as well as third-party licensed brands. The Company generates revenue through the in-game sales of virtual currency and through advertising. The company has one operating segment with one business activity, developing and monetizing social games.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.